Abstract: A system and method for adaptively utilizing transmitter windowing, receiver windowing and alignment signals for minimizing interference and maximizing capacity and energy efficiency based upon the received power ratios of links in adjacent bands of a cellular communication network.

Abstract: Isolated peptides are disclosed. The peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-5 and 11-15, with the proviso that the amino acid sequence does not consist of SEQ ID NO: 11, SEQ ID NO: 15 or SEQ ID NO: 1, wherein the peptide is no longer than 50 amino acids. Pharmaceutical compositions comprising same and uses thereof for treatment of diseases associated with serotonin transport and/or ?V?3 activity are also disclosed.

Abstract: The present disclosure relates to attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and to multivalent immunogenic compositions comprising Zika vaccines and vaccines to other flaviviruses. The chimeric Zika viruses includes a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a 3? untranslated region from a second flavivirus. The multivalent immunogenic compositions comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype 1, a second attenuated virus that is immunogenic against dengue serotype 2, a third attenuated virus that is immunogenic against dengue serotype 3, and a fourth attenuated virus that is immunogenic against dengue serotype 4.

Abstract: The present invention provides for a composition comprising: (a) a first host cell capable of producing L-DOPA; and (b) a modified host cell is capable of converting L-DOPA into hydroxytyrosol (HTy); wherein any one or both of the first host cell and second host cell is a genetically modified host cell.

Abstract: Systems and techniques for real-time, transcranial monitoring of safe blood-brain barrier opening include determining an approach angle for targeted blood-brain barrier opening proximate a predetermined region in a brain of a patient, and positioning an ultrasound transducer to generate a focused ultrasound signal at the determined approach angle to the predetermined region in the brain.

Abstract: Compositions and methods for repelling arthropods. The compositions include a carrier and an arthropod repelling compound, which can be a compound discovered by a novel and complex cheminformatic process to demonstrate repellency behavior across a broad spectrum of arthropods. The compound can be a thiane compound, a pyrrolidone compound, a cyclohexadiene compound, a cyclohexenone compound, a cyclohexene compound, a furanone compound, a pyran compound, a tetrahydropyran compound, a thiazolidine compound, a thiazoline compound, a dihydrothiophene compound, a dithiolane compound, a dithiane compound, an epoxide compound, an oxathiane compound, a cyclopentene compound, a cyclohexane compound, a quinoline compound, an oxazoline compound, a tetrahydropyridine compound, and an imidazolidinone compound, or a combination thereof.

Abstract: The present invention relates to: a cell therapeutic agent including ventral midbrain-derived astrocytes and dopamine neural progenitor cells; a method of treating a neurodegenerative disorder including administering a pharmaceutical composition comprising ventral midbrain-derived astrocytes and dopamine neural progenitor cells into a subject; and a method for differentiation into dopamine neurons, which includes preparing a mixture of ventral midbrain-derived astrocytes and dopamine neural progenitor cells and co-culturing or co-grafting the mixture. The co-grafting of ventral midbrain-derived astrocytes and dopamine neural progenitor cells (neural stem cells) improves the survival and differentiation of dopamine neurons and thus dramatically improves therapeutic outcomes in a neurodegenerative disorder including Parkinson's disease.

Abstract: The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.

Abstract: The present disclosure relates to antagonists that target Serine/Arginine-Rich Splicing Factor 1 (SRSF1); expression vectors comprising SRSF1 antagonists; and the use of such antagonists in therapy for the treatment of neurodegenerative disorders and cancer and screening methods that identify agents that inhibit the expression or activity of SRSF1.

Abstract: A shipping container for a personal watercraft, in which a first and second pair of roller guides attach to a pallet for removably receiving a pair of trusses that support a personal watercraft thereon, the trusses movable between a first position for loading or unloading the personal watercraft and a second position for storing and transporting of the personal watercraft at an oblique angle. A method of containing a personal watercraft in a shipping container is disclosed.

Abstract: The invention addresses confounding difficulties involving continuous sweat analyte measurement. Specifically, the present invention provides: at least one component capable of monitoring whether a sweat sensing device is in sufficient contact with a wearer's skin to allow proper device operation; at least one component capable of monitoring whether the device is operating on a wearer's skin; at least one means of determining whether the device wearer is a target individual within a probability range; at least one component capable of generating and communicating alert messages to the device user(s) related to: wearer safety, wearer physiological condition, compliance with a requirement to wear a device, device operation; compliance with a behavior requirement, or other purposes that may be derived from sweat sensor data; and the ability to utilize aggregated sweat sensor data that may be correlated with information external to the device to enhance the predictive capabilities of the device.

Abstract: A conductive nanoporous membrane system has a first ion exchange membrane formed from a nanoporous substrate that is coated with a metal or carbon or conductive polymers to form a conductive membrane, a second ion exchange membrane that is also formed from a nanoporous substrate coated with a metal to form a conductive membrane is positioned in spaced relation to the first conductive membrane and coupled to a voltage source; the negatively potential membrane acts as a cation exchange membrane in the presence of an electrolyte, and the positively connected electrode behave as anodic exchange membrane in the presence of an electrolyte due to the formation of electrical double layers at the interface between metal and liquid electrolyte.

Abstract: The present invention provides a method of treating melanoma and other cancers in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an herbal extract of PHY906 or Scutellaria baicalensis, a fraction thereof, or any active chemical present in the herbal extract or fraction thereof, and one or more immune checkpoint inhibitors. In certain embodiments, the method further comprises administering at least one herbal extract, a fraction thereof, or any active chemical present in the herbal extract or fraction thereof, of at least one herb selected from the group consisting of Glycyrrhiza uralensis, Paeonia lactiflora, and Ziziphus jujuba. The methods of the invention are useful for treating cancer such as melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and/or pancreatic cancer.

Abstract: The invention addresses confounding difficulties involving continuous sweat analyte measurement. Specifically, the present invention provides: at least one component capable of monitoring whether a sweat sensing device is in sufficient contact with a wearer's skin to allow proper device operation; at least one component capable of monitoring whether the device is operating on a wearer's skin; at least one means of determining whether the device wearer is a target individual within a probability range; at least one component capable of generating and communicating alert messages to the device user(s) related to: wearer safety, wearer physiological condition, compliance with a requirement to wear a device, device operation; compliance with a behavior requirement, or other purposes that may be derived from sweat sensor data; and the ability to utilize aggregated sweat sensor data that may be correlated with information external to the device to enhance the predictive capabilities of the device.

Abstract: Described herein are methods for making and using magnetic ionic liquid that have at least one cationic component and at least one anionic component, where at least one of the cationic components or the anionic components is a paramagnetic component. The magnetic ionic liquids are capable of manipulation by an external magnetic field.

Abstract: An AC excitation synchronous condenser and a control method, an AC-excitation induction machine, a full-controlled AC excitation converter, a grid-side converter and a controller. The AC-excitation induction machine is the core power converting device, and its stator and rotor windings are AC windings with terminals. The controller is configured to control the full-controlled AC excitation converter to perform excitation and speed regulation on the AC-excitation induction machine and also control the grid-side converter to ensure the excitation capability of the full-controlled AC excitation converter, so that support and regulation of the active power and reactive power are achieved.

Abstract: A signal transmission device and method, and a signal reception device are disclosed.

Abstract: Herein, 8-substituted guanine and/or 8-substituted guanosine compounds are used in methods to treat hypertension (such as systemic or pulmonary hypertension), stroke, diabetes, and/or patients in need of a diuretic. In addition, 8-substituted guanine and/or 8-substituted guanosine compounds are included in a beverage composition, which can be a fermented beverage, such as wine. Further, purine nucleoside phosphorylase (PNPase) inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can be used in methods of treating or reducing the risk of pulmonary hypertension (PH), such as PH associated with HIV or sickle cell disease (SCD). PNPase inhibitors (such as 8-substituted guanine and/or 8-substituted guanosine) and/or PNPase purine nucleoside substrates (such as guanosine and/or inosine) can also be used in methods of treating SCD or reducing sickling of red blood cells (RBCs).

Abstract: A laser light containment dome providing increased safety to microscopy users while allowing the microscopy instrument to be used in an effective and efficient manner is provided. The laser light containment dome includes a hemisphere or dome shaped enclosure that prevents dangerous intensities of laser light from exiting an objective lens and or microscopy sample holder while still allowing the user to witness and measure the direction of laser light in three dimensions.

Abstract: A polarization plenoptic camera that can acquire the polarization information of reflected light from an object in a single shot; i.e., in real time, to avoid issues such as motion blur and also avoid the additional system complexity that derives from mechanical scanning of a polarizer. The camera includes a polarization-sensitive focal plane array, a first microlens array having a pitch that is equal to a pitch of the pixel array; and either a second microlens array having a pitch that is greater than the pitch of the pixel array, a coded aperture mask, or a second microlens array and a coded aperture mask. A method for obtaining a plenoptic image of an object scene is disclosed.